Zanubrutinib, Tislelizumab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-31 in 3mo
ESTIMATED |
READOUT
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants Wi
Phase 3 · B-cell Malignancies |
ONC BeOne Medicines Ltd. | Zanubrutinib, Tislelizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|